Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Disitamab vedotin |
| Synonyms | |
| Therapy Description |
Disitamab vedotin (RC48) is an antibody-drug conjugate comprising a monoclonal antibody that targets HER2 (Hertuzumab) linked to the cytotoxic drug MMAE, which delivers the cytotoxic agent to HER2-expressing tumor cells, potentially resulting in increased cell death (PMID: 27509865, PMID: 31877330). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Disitamab vedotin | RC48|Hertuzumab-vc-MMAE|RC-48 | HER2 (ERBB2) Antibody 76 | Disitamab vedotin (RC48) is an antibody-drug conjugate comprising a monoclonal antibody that targets HER2 (Hertuzumab) linked to the cytotoxic drug MMAE, which delivers the cytotoxic agent to HER2-expressing tumor cells, potentially resulting in increased cell death (PMID: 27509865, PMID: 31877330). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06157892 | Phase Ib/II | Disitamab vedotin + Tucatinib Disitamab vedotin | A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
| NCT04879329 | Phase II | Disitamab vedotin Disitamab vedotin + Pembrolizumab | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Recruiting | USA | ITA | ISR | GBR | ESP | CAN | BEL | AUS | ARG | 2 |
| NCT06003231 | Phase II | Disitamab vedotin | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Active, not recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
CKB BOOST